Philip Morris Just Raised Its Dividend. The Stock Isn't Buying It.

# Philip Morris Just Raised Its Dividend. The Stock Isn't Buying It.

Philip Morris International walked into summer with one of the sharpest stories in consumer staples: a record $11.2 billion quarter, smoke-free products now 42% of revenue, and a management team that kept raising guidance even as the world got louder. Then it delivered the Q2 report on July 22 and, for whatever reason, the market shrugged.

Here's the thing that bothers me about how PM has been treated. The fundamentals are not just fine — they're exceptional. Record revenue. A 68.4% gross margin and a 40.5% operating margin on a company this size. $5.1 billion in free cash flow from $5.5 billion in operating cash flow in a single quarter. Adjusted EPS that beat consensus, with guidance raised to $8.35–$8.50 for the year. The board handed shareholders an 8.8% dividend bump to $1.60 a share on September 18, a 3.1% yield with an ex-date of October 2. UBS lifted its target to $193, blended analyst targets are near $210.

And yet the stock sits near its 52-week high of $207.76 having underperformed the S&P 500 over the past year, and it has earned a rich ~27x trailing multiple against a peer average of ~22x. Nobody is calling it cheap. Nobody is even calling it interesting.

That is the setup, and it's a funny one.

Let's talk about the elephant in the smoke-free room: ZYN. U.S. pouch growth collapsed to 1.8% in Q2. That number is the single biggest threat to the entire bull case, and it deserves every ounce of skepticism it's getting. PMI responded the way a company with a real product pipeline does — new SKUs, ZYN ULTRA, additional flavors — and it landed a genuine regulatory milestone, FDA modified-risk authorization for 20 ZYN variants, allowing lower-health-risk claims. But notice what happened to the stock on that news: it dipped ~1.2%. The market had already priced the approval and was looking at the growth deceleration. A regulatory win that should be a positive got absorbed by a growth number that shouldn't be this bad.

Here's my actual point of view, and I'll defend it: the bears are right about the risks and wrong about the price.

The bear case is not weak. Read it carefully and you'll see real substance. A structurally weak balance sheet — negative stockholders' equity at -$8.58 billion, roughly $49 billion in debt, a 0.98 current ratio. A reported EPS that fell 7.7% on a ~$511 million impairment in the Canadian affiliate Rothmans Benson & Hedges. A ZYN deceleration that, if it persists, reframes the whole growth thesis. And a ~27x multiple that offers zero margin of error when the next print comes in. Any of those can hurt, and the negative-equity situation is the kind of structural fragility that gets ignored until it doesn't.

But "the risks are real" and "the stock is a sell" are not the same sentence. PM is a cash-flow compounder trading at a premium for exactly the qualities that are now being weaponized against it. The combustibles business is structurally shrinking — that's known, priced, and the whole free-cash-flow machine keeps running anyway. FX is a headwind, not a crisis. The RBH impairment is a one-time hit, not a business-model problem.

The technicals tell the same cautionary tale, and I'll give them their due. The stock is in a clear uptrend but sitting barely above its short-term moving averages — 0.78% above the 20-day, 0.52% above the 50-day — with neutral momentum. The kind of read that says "accumulation on weakness, not a chase at $192." The model's forecast band sketches a near-term pullback toward $169–$170 before stabilization, with $164 as the line in the sand and the $207.76 high as the only real breakout trigger. And worth being honest about: that directional model has been beaten by a naive baseline on the short horizons, so treat the forecast band as a map, not a prophecy.

So what am I actually saying? I'm saying this is a medium-term accumulation story wearing a near-term "wait for a better price" face. The business is firing on all cylinders. The dividend is growing. The smoke-free target of more than two-thirds of revenue by 2030 is within reach. But you are not being paid to own it at $192 when it trades at 27x earnings and ZYN growth is hovering at single digits.

The next catalyst is the calendar's big one: Q3 earnings, expected October 20, before the open. That's the moment the ZYN question gets answered and the raised guidance gets tested. If growth keeps decelerating, that $21x forward multiple won't protect you. If it stabilizes, the current trajectory has room to run toward the $210–$215 analyst levels.

My read in one line: the story is real, the balance sheet is the thing to watch, and the only sensible move is to let $169 come to you rather than chasing $207. PM isn't a momentum trade right now. It's a patience trade — and patience, unlike this multiple, hasn't been fully rewarded yet.